Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects.
Osocimab (1.4 nM-1 μM; 30 min) inhibits thrombin generation, and also inhibits FXIa-mediated activation of FIX (FIX conversion) (IC50=16 nM) and FXIa mediated substrate cleavage (IC50=1.2 nM) in human plasma[1].
Osocimab (22.05 mg/mL) inhibits intrinsic pathway-mediated activation of the coagulation cascade[1].
References:
[1]. Schaefer M, et al. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J Mol Biol. 2019 Dec 6;431(24):4817-4833.